Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$42.57 USD

42.57
739,250

-0.06 (-0.14%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $42.57 0.00 (0.00%) 6:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (164 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Indrajit Bandyopadhyay headshot

3 Medical Device Stocks With Potential to Fight Recession Risk

by Indrajit Bandyopadhyay

The decline in U.S. GDP during the first quarter and 26% decline in the S&P 500 Index so far this year fuel the risk of a recession. MCK, PDCO & AMN have the potential to help investors ward off volatility risks going forward.

AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, AMN Healthcare Services (AMN) closed at $122.77, marking a +1.37% move from the previous day.

Here's Why You Should Retain Chemed (CHE) Stock For Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE) owing to the robust demand for Roto-Rooter services and the ongoing rebound in senior housing admissions.

NextGen (NXGN)-InstaMed Ink Deal to Improve Payment Processing

by Zacks Equity Research

NextGen's (NXGN) latest expanded deal with InstaMed is expected to significantly simplify payment methods for both patients and providers.

3 Reasons to Retain DaVita (DVA) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care.

Here's Why Momentum in AMN Healthcare (AMN) Should Keep going

by Zacks Equity Research

AMN Healthcare (AMN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Here's Why You Should Retain Fresenius Medical (FMS) Stock Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

The Zacks Analyst Blog Highlights AMN Healthcare, Boeing, Clorox, Novo Nordisk and Costco Wholesale

by Zacks Equity Research

AMN Healthcare, Boeing, Clorox, Novo Nordisk and Costco Wholesale have been included in this Analyst Blog.

Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Alcon's (ALC) Product Launches, Market Recovery Aid Growth

by Zacks Equity Research

Despite bearing the brunt of inflationary pressure across both Total Surgical and Vision Care franchises, Alcon (ALC) succeeds in mitigating much of the impact through cost-improvement efforts.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: AMN Healthcare, Boeing, Clorox, Home Depot in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.

3 Reasons Why BD (BDX) is a Great Pick For Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

Here's Why Investors Should Retain Phibro (PAHC) For Now

by Zacks Equity Research

Investors are optimistic about Phibro's (PAHC) major animal health products and robust vaccine sales.

LabCorp (LH) Debuts NfL Test for Neuronal Damage Diagnosis

by Zacks Equity Research

LabCorp's (LH) widely accessible NfL blood test presents direct evidence of neuronal injury resulting from brain injury or diseases like Alzheimer's, among others.

Here's Why You Should Buy DENTSPLY SIRONA (XRAY) Stock Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Fresenius (FMS) Faces Fraud Accusation From US Government

by Zacks Equity Research

The Department of Justice of the U.S. government files a civil complaint against Fresenius (FMS), accusing it of defrauding Medicare and other healthcare programs by billing for unnecessary procedures.

Zacks.com featured highlights include AMN Healthcare Services, Otter Tail, Encore Capital Group and Cboe Global Markets

by Zacks Equity Research

AMN Healthcare Services, Otter Tail, Encore Capital Group and Cboe Global Markets are part of zacks Screen of the week article.

Derek Lewis headshot

This Medical Supplier Is Pushing All-Time Highs

by Derek Lewis

McKesson shares have been scorching-hot year-to-date, increasing by more than 30% in value and extensively outperforming both its Zacks Sector and the S&P 500.

AMN Healthcare Services (AMN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed the most recent trading day at $110.24, moving -1.09% from the previous trading session.

Here's Why You Should Retain Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher's (TMO) strong end market growth and noteworthy acquisitions.

3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.

CVS Health (CVS) Pharmacy Claims Volume Grows, Margin Woes Stay

by Zacks Equity Research

CVS Health's (CVS) investments in constructing affordable housing units in Denver, Fresno, Nashville and San Antonio seem encouraging.

AngioDynamics (ANGO) Q4 Earnings in Line, Revenues Beat Mark

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in Med Tech and Med Device businesses, as well as in its GBUs, in fourth-quarter fiscal 2022.

Haemonetics (HAE) Hospital Arm Thrives, Gross Margin Rises

by Zacks Equity Research

Strong procedure recovery in the hospital business, the resilience of blood donors in blood centers and rollouts of Persona technology and NexSys aid Haemonetics (HAE).